New-onset heart failure due to heart muscle disease in childhood: A prospective study in the United Kingdom and Ireland

Circulation

Volumn 117, Issue 1, 2008, Pages 79-84

  Andrews, Rachel E ^a   Fenton, Matthew J ^b   Ridout, Deborah A ^c   Burch, Michael ^b  

^a EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiomyopathy; Morbidity; Mortality; Myocarditis; Transplantation

Indexed keywords

ANTICOAGULANT AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT;

ADOLESCENT; AGE; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CONFIDENCE INTERVAL; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; DEATH; ECHOCARDIOGRAPHY; EXTRACORPOREAL OXYGENATION; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; INFANT; IRELAND; LEFT VENTRICULAR NONCOMPACTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MYOCARDIAL DISEASE; MYOCARDITIS; NEWBORN; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK; SURVIVAL; SYSTOLE; TOXICITY; UNITED KINGDOM;

ADOLESCENT; AGE FACTORS; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; GREAT BRITAIN; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; IRELAND; MYOCARDITIS; MYOCARDIUM; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SYSTOLE; TREATMENT OUTCOME;

EID: 37349059659     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.671735     Document Type: Article

References (24)

1. Boucek MM, Waltz DA, Edwards LB, Taylor DO, Keck BM, Trulock EP, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report: 2006. J Heart Lung Transplant. 2006;25:893-903.
2. Chen SC, Nouri S, Balfour I, Jureidini S, Appleton RS. Clinical profile of congestive cardiomyopathy in children. J Am Coll Cardiol. 1990;15:189-193.
3. Lewis AB, Chabot M. Outcome of infants and children with dilated cardiomyopathy. Am J Cardiol. 1991;68:365-369.
4. Wiles HB, McArthur PD, Taylor AB, Gillette PC, Fyfe DA, Matthews JP, Shelton LW. Prognostic features of children with idiopathic dilated cardiomyopathy. Am J Cardiol. 1991;68:1372-1376.
5. Burch M, Siddiqi SA, Celermajer DS, Scott C, Bull C, Deanfield JE. Dilated cardiomyopathy in children: determinants of outcome. Br Heart J. 1994;72:246-250.
6. Griffin ML, Hernandez A, Martin TC, Goldring D, Bolman RM, Spray TL, Strauss AW. Dilated cardiomyopathy in infants and children. J Am Coll Cardiol. 1988;11:139-144.
7. Arola A, Tuominen J, Ruuskanen O, Jokinen E. Idiopathic dilated cardiomyopathy in children: prognostic indicators and outcome. Pediatrics. 1998;101:369-376.
8. Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela A, Tikanoja T, Paavilainen T, Simell O. Epidemiology of idiopathic cardiomyopathies in children and adolescents: a nationwide study in Finland. Am J Epidemiol. 1997;146:385-393.
9. Nugent AW, Daubeney PEF, Chondros P, Carlin JB, Cheung M, Wilkinson LC, Davis AM, Kahler SG, Chow CW, Wilkinson JL, Weintraub RG. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348:1639-1646.
10. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348:1647-1655.
11. United Kingdom and Northern Ireland population data. Office for National Statistics Web site. Available at: www.statistics.gov.uk. Accessed March 2007.
12. Ireland population data. Central Statistics Office Ireland Web page. Available at: www.cso.ie. Accessed March 2007.
13. Miura K, Nakagawa H, Morikawa Y, Sasayama S, Matsumori A, Hasegawa K, Ohno Y, Tamakoshi A, Kawamura T, Inaba Y. Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. Heart. 2002;87:126-130.
14. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria [review]. Circulation. 2006;113:593-595.
15. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006;113:876-890.
16. Goldman AP, Cassidy J, DeLeval M, Haynes S, Brown K, Whitmore P, Cohen G, Tsang V, Elliott M, Davison A, Hamilton L, Bolton D, Wray J, Hasan A, Radley-Smith R, Macrae D, Smith J. The waiting game: bridging to paediatric heart transplantation. Lancet. 2003;362:1967-1970.
17. McMahon A, Van Doorn C, Burch M, Whitmore P, Neligan S, Rees P, Radley-Smith R, Goldman A, Brown K, Cohen G, Tsang V, Elliott M, de Leval M. Improved early outcome for end-stage dilated cardiomyopathy in children. J Thorac Cardiovasc Surg. 2003;126:1781-1787.
18. Tsirka AE, Trinkaus K, Chen SC, Lipshultz SE, Towbin JA, Colan SD, Exil V, Strauss AW, Canter CE. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol. 2004;44:391-397.
19. Grimm W, Christ M, Bach J, Muller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg. Circulation. 2003;108:2883-2891.
20. Friedman RA, Moak JP, Garson A Jr. Clinical course of idiopathic dilated cardiomyopathy in children. J Am Coll Cardiol. 1991;18:152-156.
21. Anversa P, Leri A, Rota M, Hosoda T, Bearzi C, Urbanek K, Kajstura A, Bolli R. Concise review: stem cells, myocardial regeneration and methodological artifacts. Stem Cells. 2007;25:589-601.
22. Leversha AM, Wilson NJ, Clarkson PM, Calder AL, Ramage MC, Neutze JM. Efficacy and dosage of enalapril in congenital and acquired heart disease. Arch Dis Child. 1994;70:35-39.
23. Bruns LA, Chrisant MK, Lamour JM, Shaddy RE, Pahl E, Blume ED, Hallowell S, Addonizio LJ, Canter CE. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr. 2001;138:457-458.
24. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, Redha E, Marin JR, Lon-Young M, Wolff GS. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant. 2004;23:832-838.